Association of Serum Uric Acid Levels in Acute Ischemic Stroke by Harikrishnan, J
ASSOCIATION OF SERUM URIC ACID LEVELS 
IN ACUTE ISCHEMIC STROKE 
Dissertation submitted to 
THE TAMILNADU DR. M.G.R MEDICAL UNIVERSITY 
CHENNAI 
 
In partial fulfilment of regulations 
For award of the degree of 
M.D (GENERAL MEDICINE) 
BRANCH – 1 
 
 
 
         KILPAUK MEDICAL COLLEGE 
CHENNAI    600 010 
April 2015 
 
  
 BONAFIDE CERTIFICATE 
 
This is to certify that dissertation named “ASSOCIATION OF SERUM 
URIC ACID LEVELS IN ACUTE ISCHEMIC STROKE” is a bonafide 
work performed by Dr.J.Harikrishnan, post graduate student, Department of  
Internal Medicine, Kilpauk Medical College, Chennai-10, under my guidance 
and supervision in fulfilment of regulations of the Tamilnadu  Dr. M.G.R 
Medical University for the award of M.D. Degree Branch I (General Medicine) 
during the academic period from May 2012to April 2015.   
 
Prof. Dr.R.Sabaratnavel M.D.,                              
Professor and Head of Department                                                                  
Department of Medicine                                                     
Kilpauk Medical College,                                                                                                                          
Chennai-14 
                                  Prof.Dr.N.Gunasekaran M.D.,D.T.C.D 
THE DEAN 
GOVERNMENT KILPAUK MEDICAL COLLEGE 
CHENNAI - 600 010. 
  
 
 
 
 DECLARATION 
 
I solemnly declare that this dissertation “ASSOCIATION OF SERUM 
URIC ACID LEVELS IN ACUTE ISCHEMIC STROKE” was prepared by 
me at Government Royapettah Hospital, Chennai, under the guidance and 
supervision of  Dr. R.Sabaratnavel M.D., Professor, Department of Internal 
Medicine, Government Royapettah Hospital, Chennai. 
This dissertation is submitted to The Tamil Nadu Dr. M.G.R. Medical 
University, Chennai in partial fulfilment of the University regulations for the 
award of the degree of M.D. Branch I (General Medicine). 
 
 
 
 
Place: Chennai 
Date:                                                                          (Dr.J.Harikrishnan) 
 
 
 
 


ACKNOWLEDGEMENT 
 
              At the outset, I would like to thank my beloved Dean, Kilpauk Medical 
College Prof Dr.N.Gunasekaran M.D.,D.T.C.D., for his kind permission to 
conduct the study in Kilpauk Medical College. I would like to express my 
special thanks to Professor and Head, Department of General medicine  
Prof. Dr.R.Sabaratnavel M.D., Govt. Royapettah Hospital  for permitting to 
conduct this study.  
             I would like to thank wholeheartedly, Prof. Dr. R.Sabaratnavel M.D., 
Head of Department and Professor of Medicine for his encouragement and 
guidance during the study. 
              I also express my thanks to Prof. Dr.Mayilvahanan M.D., I am 
extremely thankful to Assistant Professors of Medicine, Dr.S.Gopalakrishnan 
MD, Dr.S.Malathi MD and Dr.V.Madhavan MD., for their assistance and 
guidance.  
I would always remember with extreme sense of thankfulness, the co-operation 
and constructive criticism shown by my fellow post graduate colleagues and 
friends. I would like to thank my parents and my brother for their prayers and 
support.  
I would like to thank my wife and son. Without them it would not have been 
possible. They were my constant strength and support in carrying out this study.   
I would like to thank my co-pg, Dr.Ramya.A for being a constant source of 
inspiration. I would like to thank my co-pg Dr.Sivanesan, Dr.Narayanan, 
Dr.Saranya, Dr.Aravind and my CRRIs Dr.Vel and Dr.Venkat. I would like to 
thank the staffs and technicians of GRH. 
Finally, I thank all my patients for their active co-operation in this study, 
without which this would not have become a reality. 
 
 
 
 
 
 
 
 
 
 
SL.NO CONTENTS PAGE NO 
1 INTRODUCTION 1 
2 AIMS AND OBJECTIVES 2 
3 REVIEW OF LITERATURE 5 
4 METHODOLGY 53 
5 DISCUSSION 91 
6 CONCLUSION 94 
7 BIBLIOGRAPHY 95 
8 ANNEXURES 100 
 
                                                    ABSTRACT 
BACKGROUND: 
                For decades the role of Uric acid as a independent risk factor for non-
communicable disease is a subject of discussion. Serum Uric acid is a powerful 
antioxidant that scavenge many harmful free radicals like hydroxyl ions, 
peroxinitrite along with other anti-oxidants like ascorbic acid .But elevated serum 
uric acid can act as pro-oxidant that cause various inflammatory reactions .serum 
uric acid can cause endothelial dysfunction, nitric oxide reduction in cells, platelet 
dysfunction, vascular smooth muscle cells proliferation and activates RAAS.  
AIM: 
 To study the association between serum uric acid level and acute ischemic 
stroke. 
 To study the association between serum uric acid level and other risk factors 
like SHT, DM,CAD, Obesity. 
METHODS: 
This is an analytical cross sectional study done at Govt Royapettah Hospital. 
Serum uric acid levels were measured within 24hrs of onset of scute ischemic 
stroke. 50 patients were studied. Serum uric acid level was taken as 6.5mg/dl.This 
value was compared with various other variables. 
RESULTS: 
Of the study population 66% were male and 34% were female. 38% of the 
population were <60yrs ad 62% were>60 yrs of age. 76% were hemiparetic and 
24% were hemiplegic. 76% had serum uric acid <6.5mg/dl and 24% had serum 
uric acid levels >6.5mg/dl.  The study revealed the strong association between the 
serum uric acid and DM,SHT,CAD, Dyslipidemia with a p value <0.05. The study 
also revealed that the association of uric acid with age and smoking was 
insignificant with p value >0.05. All patients admitted with hemiplegia have serum 
uric level >7mg/dl which is highly significant.  
 
CONCLUSION: 
The study shows that uric acid levels may be considered as an independent 
predictor for ischemic stroke. SUA has a strong association with DM, SHT and 
CAD. 
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INTRODUCTION 
SERUM URIC ACID (SUA) is the end product of purine metabolism. 
SERUM URIC ACID (SUA) is a  subject of study for many research scholars in 
recent decades. 
 In 1882 HOFFMAN EDWARD  was the first to synthesise the uric 
acid(SUA)  in the laboratory. Millions of years ago, our hominid ancestors 
acquired two point mutation in the uricase enzyme that convert uric acid into 
allantoin. This resulted in elevated uric acid levels among humans and our great 
apes. It is postulated that SUA may be the reason for longevity of life when 
compared to other mammals.  
SUA is a powerful anti-oxidant along with VITAMIN E and VITAMIN 
C. SUA normally scavenge HYDROXYL, PEROXY NITRITE, and other pro-
inflammatory free radicals. But many recent research journals revealed that 
protective SUA under certain physio-biochemical condition may turn to be a 
toxic substance inflicting injuries to the cells.  
Association of  elevated uric acid in reducing the intra cellular nitric 
oxide causing  platelet and endothelial dysfunction , and vascular smooth 
muscle  proliferation  may be responsible for development various risk factors 
in non- communicable diseases.  Elevated NADPH OXIDASE , recruiting more 
MCP-1(monocyte chemoattractant protein) blocking L - ARGININE               
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(precursor of NO)  stimulating  PDGF ( platelet derived growth factor)  are  the 
proven effects of  elevated SUA, that clearly state that elevated SUA is toxic .       
Nearly two centuries after the discovery of SUA many papers have been 
published about its association with metabolic syndrome, cerebro vascular 
disease, coronary artery disease and gout.  ARIC (ATHEROSCLEROSIS RISK 
IN COMMUNITIES), FRAMINGHAM’S STUDY ,BRHS STUDY, 
REYKJAVIK STUDY, PROCAM STUDY, NHEFS STUDY, NHANEIS 
STUDY, revealed the association of SUA with the risk factor of NON- 
COMMUNICABLE DISEASE.   
 Among the neurological  diseases,  the  cerebrovascular diseases(CVD)  
rank the first in frequency  and importance.  At least 50% of the neurological 
disorders in a general hospital are CVD. Stroke, after heart disease and cancer is  
the  most  common  cause  of  death.  In the developing countries like INDIA 
we face dual burden of COMMUNICABLE DISEASE AND NON- 
COMMUNICABLE DISEASE. 
 The prevalence rate of Cerebro vascular disease (CVD) in INDIA is 84-
262 per 100000 persons in rural population and 334-424 per lakh persons in 
urban population. In TAMIL NADU the prevalence is around 56.9 per 100000 
persons. Recent studies reveals that increased occurrence of risk factor for 
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stroke among adult population.  All the physicians have a role to play in the 
prevention of stroke by encouraging  the reduction  in risk factors .  
Stroke also entails  a high  socio economic   burden   due   to   increased   
morbidity and   mortality. Ischemic strokes   account   for   >   80%   of   total   
stroke   events. Early identification of individuals at risk could be of help in 
primary prevention strategies.   
Since SUA is associated with all the risk factors of cerebrovascular 
disease, this study could be used to support the evidence that serum uric acid 
may be used as a early  marker for  development of cerebrovascular disease. 
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AIM OF THE STUDY 
The study is conducted to analyse the association of SERUM URIC 
ACID  levels and acute ischemic stroke and to assess its risk factor potential. 
To study the association between SERUM URIC ACID levels and other 
risk factors like CAD, SYSTEMIC HYPERTENSION, DIABETES 
MELLITUS, DYSLIPIDIMIA and others.  
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 REVIEW OF LITERATURE 
URIC ACID 
Background: 
          The study substance Serum Uric Acid (SUA) is the final product of 
Purine metabolism. In spite the study substance Serum Uric Acid was 
discovered 200 years before, the Patho-physiology and the biological actions 
have to be researched more. For years together the study substance serum Uric 
Acid was believed to be a protective molecule for humans. Recent studies have 
shown that the study substance serum Uric Acid may be a both edged sword 
under certain biochemical conditions. From the following study, various 
biochemical properties of the study substance serum Uric Acid will be 
discussed. 
CHEMISTRY OF URICACID 
            The study substance serum Uric Acid is a heterocyclic compound with 
molecular formula C5H4N4O3. 
Its Molar mass: 168.11g/mol. 
Its Melting point: 300 degree C. 
Its Acidity (pKa): 5.6 and Basicity: 8.4. 
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URICACID STRUCTURE 
  
SOURCES OF URIC ACID 
Purine sources: 
A] Dietary sources like pork, poultry, fish, beef, cauli-flower, spinach, 
mushroom, green peas, oat meal, sweet bread, sardines are rich in Uric 
acid.  
B] Degradation of endogenous nucleotides. 
C] De-novo synthesis (energy recurring process). 
Endogenous Nucleotides: 
DNA is the polymer of nucleotides; the fundamental unit of nucleic acid 
is nucleotide. DNA is found only in cell nucleus not in cytoplasm unlike the 
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RNA. Purines are biologically synthesised as nucleotides. Adenine and Guanine 
are major Purines. Uric acid is the final oxidation product. Hypo-Xanthine and 
Xanthine are intermediate products. The rate limiting step in the synthesis of 
uric acid is  catalysed by the enzyme Xanthine-Oxidase. Xanthine Oxidase 
contains molybdenum bound to sulphur and oxygen. It exists in two forms 
Xanthine Oxidase and Xanthine Dehydrogenase. 
 
                                         Nucleotide  
                           
 
1. Nucleoside       2. Phosphate 
                                     
                  a).Base             b).Sugar  
                             
            Purine , Pyrimidines 
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                       DENOVO SYNTHESIS OF URIC ACID 
 
 
 
 
 
 
 
 
 
 
 
Pathways of urate homeostasis is to produce uric acid, to convert it into 
allantoin by the liver enzyme uricase, and to excrete it. The balance between 
these pathways regulates blood urate concentrations, which are higher in 
humans and apes due to inactivation of the uricase genes. Hyperuricemia can 
lead to gout and possibly to cardiovascular effects, whereas hyperuricosuria 
may leads to uric acid crystal–induced pathologies. 
9 
 
SALVAGE PATHWAY: 
           This pathway converts the purines to their parent nucleotide and it is 
energy conserving pathway. Enzymes involved are Hypoxanthine – Guanine 
Phosphoribosyl Transferase (HGPRT) for Guanine and Hypoxanthine. Adenine 
Phosphoribosyl Transferase (APRT) for Adenine. Purine metabolism end 
product is Uric acid. Pyrimidine metabolism end product is Urea. 
                Other than some higher primates and humans, the final oxidation 
product of Purine metabolism, Uric acid is converted to Allantoin by Uricase 
enzyme. Million years ago, our hominid ancestors acquired a double step 
mutation in the gene for Uricase. Hence, they have higher level of Uric acid 
than most of the  other mammals. 
                Uricase is a hepatic enzyme that produces Allantoin. Rat, Kangaroo, 
Birds and Reptiles though the uric acid is produced, it is excreted as dry mass, 
thereby conserving water for their body. 
               In humans, uric acid is excreted in kidney and in gut. It is degraded to 
carbon-dioxide and ammonia. In humans, SUA is filtered by glomerulus, 
reabsorbed at proximal tubules, secreted at distal tubule and only 10% of the 
filtered Uric acid is excreted. The urate reabsorption pathway involves the 
apical exchanger proteins URAT1, OAT4, and OAT10; intracellular urate is 
released through basolateral Glut 9.  
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               Urate uptake by URAT1 and OAT10 is accelerated by intracellular 
monocarboxylates such as lactate, pyrazinoate, and nicotinate and by 
dicarboxylates for OAT4. Several apical monocarboxylate transporters are 
required to favour urate reabsorption, such as MCT9 and SMCT1 and -2 . The 
excretion pathway involves the basolateral urate/di-carboxylate exchangers 
OAT1 and OAT3 and the apical ATP-binding cassette proteins MRP4 and 
ABCG2, as well as the sodium/phosphate co-transporters NPT1 and NPT4. 
              Functional organization of the apical transporters is regulated by 
interactions with PDZ domains present in URAT1, NPT1, OAT4, and the 
sodium/monocarboxylate co-transporter SMCT1 and with PDZK1 and 
NHERF1; and influenced by changes in actin polymerization regulated by the 
protein CARMIL, as determined by biochemical and genetic studies .  
             Urate transport in the mouse kidney involves both the proximal and 
distal convoluted tubules (middle and lower left panels). The same urate-
transporting proteins present in humans are found in the mouse proximal 
tubules, except for Glut9, which is present at extremely low levels. In mice, in 
contrast to humans, Glut9 is present at very high levels in both the apical and 
basolateral poles of distal convoluted tubule cells. However, it is not known 
which isoform of Glut9 is present in the apical and basolateral membranes. 
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REFERENCE VALUES: 
Men: 200-430 micro mol/litre or   3.4 – 7.2 mg /dL 
Women: 140-360 micro mol/litre or 2.4 – 6.1 mg/dL 
GENETICS:  
                   The genes responsible for Uric acid excretion include SLC2A9, 
SLC16AG, SLC23A11 and PDZK1. 
                SCL2A9 is responsible for GLUT-9 isoform that transport Uricacid. 
Fig: URICACID IN PCT INVOLVING GLUT- 9 
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 Defect in the metabolism and excretion of the study molecule Uricacid 
can lead to hyper uricemia or hypo  uricemia which is mainly due to the hyper 
uricosuria and hypo uricosuria.  
CAUSES OF INCREASED URIC ACID LEVELS: 
• Physiological and environmental factors. 
• Primary Hyperuricemia.  
• Secondary Hyperuricemia. 
Primary hyperuricemia:  
• Idiopathic.  
• Von Grieke Disease due to Glucose -6- phosphatase deficiency. 
• Lesch-Nyhan syndrome due to HGPRT-ase deficiency. 
Secondary Hyperuricemia: 
• Diuretics. 
• Lactic Acidosis. 
• Keto-acidosis. 
• Low dose salycilate. 
• Renal failure. 
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• Myeloproliferative Disorders like PCV. 
• Lymphoma. 
• Leukemia. 
• Multiple myeloma. 
• Cytotoxic Therapy for malignancy. 
• Psoriasis. 
• Diet with high fructose corn syrup that inhibit the enzyme uricase. 
• Rapid reduction in Body Mass Index. 
• Prolonged fasting. 
CAUSES OF DECREASED URIC ACID LEVELS: 
• Zinc Deficiency. 
• Phosphate binders like sevelamr. 
• Iron and Molybdenum deficiency. 
• Excess of copper. 
• Congenital cause like Molybdenum cofactor deficiency and Multiple 
Sclerosis 
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URIC ACID: THE OXIDANT – ANTIOXIDANT RECENT REVIEWS 
               The study molecule uric acid is the major antioxidant in blood but only 
under certain physiological conditions and in normal reference values. Presence 
of Ascorbic acid is essential for the antioxidant activity. Like Ascorbic acid it is 
an electron donor and scavenges the free radicals.  
In 1800, Sir Alfred Garrod found first evidence of elevated uric acid in 
patients with gout. Hoffman Edward was first to synthesis uric acid in 
laboratory. Fredric Akbar Mohammed in Lancet paper explained the association 
of uric acid in Systemic Hypertension. 
             Later, many researchers published various articles on uric acid and its 
association with Coronary Artery disease, Chronic Kidney Disease, Cerebro- 
Vascular disease, Metabolic syndrome, Obesity and Systemic Hypertension. 
Fig: OXIDANT – ANTIOXIDANT PARADOX 
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URIC ACID: ANTIOXIDANT  
Kellog and Friedrich described the mechanism by which the study 
molecule scavenges the oxygen radicals and protects the RBC membrane from 
lipid oxidation. 
Uric acid protect the Hemoglobin from auto- oxidation and peroxide 
effects of macrophages.In Nervous system disorders , particularly in Multiple 
scelerosis, Parkinsonism and acute stroke the role of  the study molecule is well 
recognized. 
Eventhough, chronic elevation of uricacid is associated with increased 
stroke risk in acute condition the study molecule has some productive value 
which is to be researched further. 
From the mouse model of experimental allergic encephalomyelitis, the 
study molecule increases the Blood Brain Barrier and thereby decreases the 
infiltration by leucocytes. They also block the peroxinitrite (ONOO) mediated 
nitrosylation of neural proteins. Excess Bicarbonate and reduced Ascorbic acid 
significantly inhibits the Antioxidant activity. 
Antioxidant activities include: 
(1)  Peroxynitrites (ONOO–) are produced from the reaction of nitric oxide 
(NO•) with superoxide (O2–•). Peroxynitrites can induce protein nitrosation and 
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lipid and protein peroxidation and block tetrahydrobiopterin (HB4), a cofactor 
necessary for NOS activity. In the absence of HB4, NOS produces ROS. Uric 
acid (UA) can directly inactivate peroxynitrite by a reaction that generates uric 
acid radicals (UA•); these can be rapidly eliminated by plasma ascorbic acid. 
(2) Uric acid can also prevent Cu2+-induced oxidation of LDL, a reaction that 
may protect against atherosclerosis development. 
(3) By enhancing arginase activity, uric acid diverts l-arginine from NO 
production to urea production. Uric acid can also directly react with NO to 
generate nitrosated uric acid, and the nitroso group can then be transferred to 
glutathione (GSH) for transport to another recipient molecule.  
Fig: URIC ACID – PEROXINITRITE ANTIOXIDANT MECHANISM 
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Fig: PRO-OXIDANT  -  ANTIOXIDANT  MECHANISM 
 
 
 
 
 
 
 
 
 
URIC ACID :  A PRO-OXIDANT 
Persistent higher value of Uric acid with elevated fructose levels in absence of 
anti-oxidants like Ascorbic acid cause activation of fructo-kinase with ATP 
consumption. This further increases the study molecule and reduction in 
intracellular ATP. This results in oxidative stress and release of inflammatory 
cytokines.  
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The following are the mechanisms of pro oxidant study molecule.  
• Endothelial dysfunction. 
• Reduction of intra cellular NO. 
• RAAS activation. 
• Excess of sympathetic nervous system activation. 
• Vascular smooth muscle cells activity alteration. 
• Increased cell membrane lipids oxidation. 
• Promote atheroscelerosis by its LDL oxidation action. 
 
Free radicals associated with Uric acid represents different degrees of 
degradation, the radical site found in the five membered ring of purine structure. 
Aminocabonyl, a carbon centered radicals associated with purine 
structure breakdown, formed from ONOO attack. The study substance at 
concentration more than 500 micro-grams amplifies the oxidation of LDL by 
peroxinitrite and LDL oxidation. They also propagate the oxidative damage. Of 
all cellular components lipids are predominantly affected. Presence of copper 
promotes the oxidation reactions of the study molecule. Lipids molecules play 
an important role in converting uric acid – a pro-oxidant.  
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Inclusion of Uric acid in to the vessel wall (media of blood vessels) result 
in additional generation of reactive oxygen species. 
The Uric acid actions are attenuated by N-acetyl cysteine, DPI, NADPH 
oxidase inhibitors and apo- cyanine.The study molecules also interfere with the 
electron transport chain and cause ATP depletion, causing an oxidative stress 
injury. 
Nitric Oxide(NO), described initially as an endothelial cell–derived 
relaxing factor, is an important regulatory molecule in the cardiovascular 
system, and reduced NO levels is associated with hypertension and insulin 
resistance. Urate can react directly with NO under aerobic conditions to 
generate an unstable nitrosated uric acid product that can transfer NO to other 
molecules such as glutathione.  
Under anaerobic conditions, urate is converted in the presence of NO into 
stable 6-aminouracil. The possibility that increased urate plasma levels can 
reduce NO bioavailability has been tested in rats treated with the uricase 
inhibitor oxonic acid. The consequent increase in plasma uric acid was indeed 
associated with a decrease in plasma nitrites/nitrates (NOx). 
Similarly, direct exposure of endothelial cells to uric acid slightly reduces 
basal or VEGF-stimulated NO production. Thus, uric acid can dose-dependently 
reduce NO bioavailability. 
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Although a direct chemical reaction of urate with NO could explain the 
decrease in plasma NOx, there is evidence that in vivo urate can decrease NO 
production by interfering with its biosynthesis. 
The SUA increases the NADPH oxidase activity, especially its isoform 
NOX4, NOX3 and classical NOX2. NOX activation causes translocation of 
regulatory sub units’ p40ph0x from cytoplasm to cell membrane promoting the 
pro inflammatory activity. 
Another pro-oxidant action of urate has been described during adipogenic 
differentiation of 3T3-L1 cell. When these cells are induced to differentiate into 
adipocytes, addition of uric acid at physiological concentrations further 
increases ROS production by a mechanism that involves activation of NADPH 
oxidase. This effect in adipocytes may participate in the induction of 
inflammation and insulin resistance of adipose tissue observed in obesity. In 
vascular smooth muscle cells, uric acid has been reported to stimulate MCP-1 
production following activation of NF-κB, MAPKs, and cyclooxygenase 2. 
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Fig: URIC ACID AND ENDOTHELIAL DYSFUNCTION 
 
 
 
 
 
 
Fig: MECHNANISM OF ENDOTHELIAL DYSFUNCTION 
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In the presence of oxygen, uric acid reacts with NO to produce the stable 
species 6-aminouracil. Uric acid uptake in adipocytes activates NADPH oxidase and 
increase production of ROS, which can initiate an inflammatory reaction.             In 
vascular smooth muscle cells, uric acid can activate the NF-κB and MAPK pathway 
and increase cyclooxygenase and MCP-1 production. The available information 
indicates that uric acid has complex chemical and biological effects and that its pro-
oxidant or NO-reducing properties may explain the association among hyperuricemia, 
hypertension, the metabolic syndrome, and cardiovascular disease.  
In addition, when hyperuricemia leads to the formation of microcrystals, it 
leads to joint and renal inflammation. Chronic inflammation (as in tophaceous gout) 
leads to bone and cartilage destruction, and chronic hyperuricemia and 
hyperuricosuria in gouty patients are also frequently associated with tubulointerstitial 
fibrosis and glomerulosclerosis, signs of local renal inflammation . 
Part of this is explained by the activation of the NALP3 inflammasome to 
process and secrete IL-1β, but other pathways of inflammation have also been 
demonstrated. 
Thus, the Uric acid major anti oxidant in our body under certain 
conditions can act as pro oxidant causing CAD , CVA , Metabolic syndrome , 
SHT  and Stroke. 
23 
 
Fig: ROLE OF URIC ACID IN THE PATHOGENESIS OF COMMON 
DISORDERS 
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CEREBROVASCULAR ACCIDENT AND URIC ACID:- 
The study molecule uric acid has been the substance of interest for 
researchers for decades regarding its neuroprotective or toxic effects. Recent 
journals have strongly implicated the study molecule as a cause for 
cerebrovascular disease.  
Uric acid induce various physiological changes in the vascular system and may 
contribute to pathogenesis of ischemic stroke. The following are the 
mechanisms of uric acid in the vascular system that leads to occurrence of 
stroke: 
• Dysfunction of the Endothelial cells.  
• Activation and proliferation of smooth muscle cells in the blood vessels 
• Dysfunction of platelets 
• Reduction of nitric oxide levels 
• Oxidation of cell membrane lipids   
• Promote atherosclerosis 
ARIC (ATHEROSCLEROSIS RISK IN COMMUNITIES STUDY) came 
out with the report that elevated uric acid was directly and significantly 
associated with ischemic stroke. 
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B-mode ultrasound of the carotid measuring the intima medial thickness was 
directly proportional to the level of serum uric acid. Ischemia involving the 
central nervous system are associated with elevated levels of xanthine oxidase.       
Elevated uric acid level is directly proportional to enzyme xanthine oxidase. 
Xanthine oxidase is a pro-inflammatory substance that promote the 
formation of various free radicals , elevates the protease level and increase the 
intracellular calcium level and cause cellular damage. The level of damage may 
be assesed by the elevated xanthine oxidase level which is the marker of 
elevated uric acid. 
Chi Kung Kum, Beon Joom Kim came out with a study that elevated 
levels of study molecule may cause Cerebral micro bleeds (CMB). Subclinical 
vascular brain lesions are easily visualized by brain magnetic resonance image 
(MRI). The lesion findings are generally classified into ischemia-prone and 
hemorrhage-prone microangiopathy . The former has been referred as white 
matter lesions (WMLs) or leukoaraiosis seen on T2-weighted or fluid-
attenuated inversion recovery MRI .The latter was recently identified, and has 
been frequently called cerebral microbleeds (CMBs). Because the nature of 
these lesions is small bleeding from the advanced lipohyalinized arterioles due 
to chronic hypertension, the CMBs have been understood to be a harbinger of 
cerebral ischemia. 
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A recent report has indicated that increased levels of uric acid are 
positively associated with large WMLs . Given a proven association between 
uric acid and vascular disease, it was  hypothesized that levels of uric acid are 
related with the presence of CMBs.Elevated CMB’s above the baseline  
immediately after stroke clearly shows that uric acid may be related to stroke. 
Further studies are neede to find an association between levels of uric acid and 
presence of CMBs in a large-sized consecutive series of ischemic stroke 
patients.              
Xanthine Oxidase Inhibitor ALLOPURINOL has been used in the 
treatment of hyperuricemia may benefit the patient with stroke. FEBUXOSTAT 
also inhibits xanthine oxidase but with reduced renal complications. Practical 
application of the conclusion deserves strong thought and research URIC ACID, 
the strong anti-oxidant may have a role in acute ischmic stroke along with other 
anti-oxidants like Vitamin-C and Vitamin-E . SUA (serum uric acid) supress the 
FENTON’s reaction, detoxify OH- and peroxynitrite free radicules. But chronic 
elevation of serum uric acid has been found to play a role in disease  
pathogenesis. Precise role of uric acid in cerebro vascular disease is still matter 
of ongoing research.   
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CORONARY ARTERY DISEASE AND URIC ACID:- 
Since 1900, the role of uric acid in syndromeX (Metabolic syndrome) has 
been widely studied. Metabolic syndrome related to cardiovascular disease have 
the following criteria based on nutritional cholestrol educational program 
ATPIII. 
• Abdominal obesity  
• Dyslipidemia 
• Raised blood pressure 
• Insulin resistance+/- glucose intolerance 
• Pro-inflammatory state 
• Pro-thrombotic state 
FRAMINGHAM”S STUDY, the largest ongoing clinical trial studied the 
role of uric acid in coronary artery disease has been studied. The outcome of the 
study clearly stated that the SUA have been associated with cardiovascular 
disease and metabolic syndrome. But it was not mentioned as an independent 
risk factor. 
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SUA, the study molecule uric acid cause stimulation of renin-angiotensin-
aldosterone system and may contribute to the development of cad apart from 
development of renal vascular constriction.  
Increased hs-CRP, fibrinogen, plasminogen activation inhibitor induces 
pro-inflammatory changes in the adipocytes and  promote the occurrence of 
acute ischemic events. 
HYPERTENSION AND URIC ACID:- 
A decade ago mohamed fredrick investigated and found in gout patient 
that elevated blood pressure in the study patient may be due to elevated uric 
acid. RENAL study have clearly came out that uric acid is an independent risk 
factor for hypertension. Elevated SUA has been found to cause RAS activation 
and hence can cause SHT. They promote the renal arteriosclerosis. In kidney, 
urate deposition occur due to prolonged hyperuricemia. Intracellular nitric oxide 
is reduced so vasodilatation does not occur on stress. 
Phase 1: Reversible Vasoconstriction 
Uric Acid + Increased renin= uric acid dependent sodium resistant vessel 
wall. This phase responds to xanthine oxidase inhibitors. Intervention can alter 
the disease  
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Phase 2: Arteriolar Wall Thickening 
Decreased NO+Uric Acid + Vascular smoothmuscle proliferation= uric acid 
independent sodium independent vessel wall. 
The second phase, which develops over time, is uric acid mediated 
arteriolosclerosis. Uric acid uptake into vascular smooth muscle cells causes the 
activation and elaboration of production of growth factor (PDGF) and monocyte 
chemoattractant protein-1 (MCP- 1). This results in the autocrine stimulation of 
vascular smooth muscle cell proliferation, vascular wall thickening, loss of 
vascular compliance, and a shift in pressure natriuresis. 
DIABETES MELLITUS AND URIC ACID:- 
Uric acid have various effects in the body in  association with diabetes like:  
• SUA cause mitochondrial oxidative stress leads to fatty liver- This results 
in insulin resistance(IR) - HEPATIC EFFECT. 
• SUA in adipocytes promotes NADPH oxidase that cause lipid oxidation 
and release super oxide radicals, MCP1 and also reduces adiponectin.This 
results in increased IR and leptin overexpression in visceral fat-ADIPOSE 
EFFECT. 
• SUA cause reduced nitric oxide by blocking L-arginine results in IR and 
endothelial cell dysfunction- VASCULAR EFFECT. 
30 
 
• SUA promote macrophage induced hyalinosis cause islet cell destruction 
by pro-inflammatory substances and results in type2 DM- ISLET CELL 
EFFECTS. 
• SUA block the ability of insulin to deliver glucose to skeletal muscle - 
MUSCLE EFFECT. 
                 Fig: URICACID AND INSULIN RESISTANCE 
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CEREBRO VASCULAR DISEASES:- 
It is one of the most common disorders that devastate humans with 
increasing age. It is a global problem involving both the developing and the 
developed worlds. Increase in the incidence of stroke increases with age. The 
increased incidence is associated with a direct increase in the morbidity and 
mortality of the patients. The risk factiors for stroke are varied and their 
prevalence is increasing in the modern world. With the increase in the risk 
factors, the incidence of stroke also increases. 
 
CHARACTERISTICS OF CVD: 
• Onset is abrupt 
• Characteristic neurological deficit 
• Causes – Vascular 
• Diagnosis is by clinical examination and relevant imaging modalities 
 
Stroke is abrupt as if struck by the hand of God.  
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Fig: CLASSIFICATION OF CEREBROVASCULAR ACCIDENT 
 
Definition and types: 
Transient ischemic attack: 
The neurological synptoms and signs resolves in 24 hrs regardless of 
imaging evidence. 
Stroke : 
The neurological syptoms and signs persist for more than 24hrs 
Syncope:  
Transient loss of consciousness due to generalised reduction of cerebral 
blood flow. This can be due to reduced cardiac output leading to systemic 
hypotension. 
CEREBROVASCULAR 
ACCIDENT 
CEREBROVASCULAR 
ANOMALIES 
 
ISCHEMIC STROKE HEMORRHAGIC 
STROKE 
1. INTRACRANIAL 
ANEURYSMS 
2. AVM 
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 5 Seconds syncope is Dizziness. 
10 Seconds Syncope – Unconsciousness. 
15 Seconds – Convulsions. 
Maximum duration of syncope is 30 seconds. 
Evolving Stroke : 
 Gradual stepwise occurence of stroke. 
Completed stroke :  
 Stroke that does not progress beyond 96 hrs. 
Young stroke: 
 Stroke below the age of 45yrs. 
Lacunar stroke: 
This is due to a small infarct less tha 15mm size secondary to the disease of 
the small perforating branches. 
• Pure sensory 
• Pure motor 
• Ataxic hemiparesis 
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• Dysarthria clumpsy hand syndrome 
• Sensory motor stroke 
The major risk factor is age and hypertension which produce microatheroma, 
hypo-hyalinosis and dissection of tiny penetrating vessels.  
Hypoxic ischemic encephalopathy: 
   Its a global brain injury with cognitive changes. 
Fig: BLOOD SUPPLY OF THE BRAIN 
                                         
PATHOGENESIS: 
The main pathogenesis involves reduced blood flow to specific areas of 
the brain resuluting in ischemia and injury to that particular area. Decrease in 
cerebral blood flow to zero cause death of brain tissue within 4 – 10 minutes. 
Blood flow less than 16 – 18ml/100gm per minute of brain tissue cause 
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infarction within one hr. When the flow reduces to less than 20ml/100gm of 
brain tissue per minute may cause ischemia rather than infarction.  
The dysfunctional brain tissue surrounding the core area of infarction is 
referred to as ischemic penumbra and this is the salvagable part of the brain 
tissue during an acute cerebrovascular accident. The penumbra can be imaged 
using the perfusion-diffusion imaging method.  
Focal cerebral infarcton occurs in two distinct pathways: 
• NECROTIC PATHWAY  
• APOPTOTIC PATHWAY 
Ischemia results in neuron death by causing a reduction in the levels of 
both oxygen and glucose. As a result mitochondrial dysfunction happens and 
the amount of adenosine triphosphate produced is reduced.  
This reduction in the amount of ATP closes or reduces the activity of the 
membrane ion pumps. This causes depolarization of the neurons and as a result 
the intracellular calcium rises.  
Also, with depolarization of the neuron, the excitatory neurotransmitter, 
glutamate is released in excess and causes activation of post synaptic glutamate 
receptors. This activation inturn increases the influx of calcium there by 
contributing to neuronal damage. 
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            Free radicals that are produced by membrane lipid degradation and 
mitochondrial dysfunction futher contribute to the neuronal damage in 
cerebrovascular accident.  
            There are two other factors that can accelerate the damage to the brain 
tissue during an acute  CVD : 
• Fever – worsens brain injury during ischemia 
• Hyperglycemia - >200mg/dl. 
This stresses the importance in controlling fever and the raised blood sugar 
levels in a CVD patient. Induced moderate hypothermia, is a topic still under 
reasearch, might reduce the brain damage. 
RISK FACTORS:- 
Common causes: 
a. Increasing age 
b. Obesity 
c. Smoking 
d. Systemic hypertension 
e. Diabetes mellitus 
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f. Cardiac cause  
g. Ischemic heart disease 
h. Rheumatic heart disease 
i. Infective endocarditis 
j. Atrial fibrillation 
k. Mitral valve prolapse 
l. ASD- paradoxical embolus 
m. Dyslipidemia 
n. Hyperfibrinigenemia 
o. High alcohol intake 
p. Coagulopathies 
q. Contraceptive pills 
YOUNG STROKE:- 
a. CARDIAC CAUSE 
b. Metabolic syndrome 
c. Vasculitis 
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d. Homocystenemia 
e. Factor v mutation  
f. Defeciency of protein C and S 
g. Deficiency of anti thrombin III 
h. AV malformation 
i. Hematological causes 
Less common causes: 
Hypercoagulable state: 
 SLE 
 Anti phospholipid syndrome 
 Deficiency of Protein C 
 Deficiency of Protein S 
 Factor V leiden mutation 
 Deficiency of Anti thrombin III 
 Polycythemia 
 Thrombocytemia 
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 Homocystenemia 
Venous sinus thrombosis: 
 Pregnancy 
 Post partum 
Inflammatory bowel disease 
Intracranial infections 
FIBROMUSCULAR DYSPLASIA 
TEMPORAL ARTERITIS 
NECROTISING ARTERITIS 
NEPHROTIC SYNDROME 
VASCULITIS 
DRUGS – Amphetamines 
MOYA MOYA DISEASE 
MELAS- Mitochondrial cytopathy 
EHLERS DANLOS SYNDROME 
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CVD EPIDIOMOLOGY IN INDIA:- 
 India the fast developing country now face dual burden namely 
communicable disease(CD) and NCD. The prevalence rate (adjusted) of CVD 
varies from 88-262 per 100000in rural population and 334-424 per lakh in urban 
population. 
Incident rate is 120-145 per lakh, report based recent population West 
Bengal especially Kolkata have high incidence of case fatality rate. In TAMIL 
NADU the prevalence is about 56.9  per lakh population. Shockingly 25% of 
CVD in Tamil Nadu involves patients with age less than 45 years. Though 
“STROKE UNITS” are formed in India they are not fully equiped to be 
functional. In Tamil Nadu only few stroke units carry out thrombolysis in 
stroke. 
CLINICAL FEATURES :- 
Signs and symptoms depends upon the regions of the brain where 
ischemia occurred. CVD should be considered in any patient presenting with 
abrupt onset of neurologic deficit or alteration in the conscious level. History 
and clinical examination may not help much to differentiate between the 
ischemic and hemorrhagic stroke. 
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Worsening of symptoms within short time of onset, conscious level 
depressed to the least level, elevated blood pressure ,seizures, signs of increased 
intra cranial pressure due to mass effect may favour hemorrhagic CVD. 
The clinical features may be: 
 Motor. 
         Sensory. 
 Autonomic. 
 With cranial nerve involvement. 
Fig: CIRCLE OF WILLIS 
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Fig: BLOOD SUPPLY OF THE LATERAL SURFACE  
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Fig: BLOOD SUPPLY OF THE MEDIAL SURFACE 
 
 
 
 
 
 
 
 
 
Fig: BLOOD SUPPLY OF INTERNAL CAPSULE 
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BRAIN STEM SYNDROME:-      
Fig:PONTINESYNDROME 
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Fig:MEDULLARYSYNDROME 
 
 
 
 
 
 
 
 
MANIFESTATIONS OF CAROTID ARTERY STROKE:- 
 Visual disturbance involving single eye 
 Speech disturbance 
 Cortical type of hemi-anaesthesia 
 Recuurent TIA’S    
 Carotid bruit and  
 Stuterring hemiplegia 
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MANIFESTATIONS OF VERTEBROBASILARY STROKE:- 
 Diplopia 
 Cortical blindness 
 Thalamic syndrome 
 Drop attacks 
 Dysphagia/ dysarthria 
 Double hemiplegia 
 Dizziness 
 Lower cranial nerve involvement. 
DIFFERENTIAL DIAGNOSIS:- 
 Post seizure paralysis – Todd’s paralysis 
 Migraine with neurological deficit  
 Metabolic cause- hypoglycaemia 
 Hypertensive encephalopathy 
 Mass lesions  
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DIAGNOSTIC TESTING:- 
Laboratories:- 
In acute setting for thrombolytic therapy  
• CBC with platelets  
• PT / INR  
• aPTT 
• Blood glucose 
For evaluation  
• Lipid profile 
• HgbA1c 
• ESR 
• Blood cultures  
• ANA 
• HIV 
• Anti phospolipid antibody and SLE antibodies 
• Serum electrolytes  
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ECG 
IMAGING:- 
Non-contrast CT – to differentiate intra cranial hemmorhage from the ischemia   
 
 
 
 
 
 
 
EARLY RADIOLOGICAL CLUES FOR ISCHEMIC STROKE: 
 Insular ribbon sign (loss of definition of grey-white interface in the    
lateral margins of the insula due to oedema in the insular cortex). 
 Hyperdense middle cerebral artery sign. 
 Hypoattenuation in the lentiform nucleus.  
 Sulcal obliteration and Loss of grey-white matter differentiation. 
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Fig: ISCHEMIC STROKE:- 
 
 
 
 
 
 
 
 
 
MRI:–  
 Most sensitive investigation of choice for CVD DIAGNOSIS. 
 Diffusion weighted MRI detect stroke the earliest. 
 In diagnosis of Posterior stroke. 
 SEQUENCE IMAGING MRI detects intra and extra cranial arterial 
dissection. 
 MRA/MRV detect occlusion involving the large artery and veins. 
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CAROTID DOPPLER- 
  non-invasive estimation of carotid stenosis for anterior circulatory 
stroke. 
2D-TT-ECHO for intra cardiac thrombus, valve vegetations, valvular 
insufficiency and stenosis. 
TEE may be needed sometimes for left atrial thrombus. 
DIAGNOSTIC PROCEDURE:- 
CEREBRAL ANGIOGRAM – DEFINITE STUDY for malformation of vascular 
structures and for performing end arterectomy of Carotid (CEA) 
LUMBAR PUNCTURE – if CT negative and high suspicion of SAH, LP is 
done. Tubes 1 and 4 should be sent for cell count. Dramatic decrease of RBC 
from 1 to 4 tube indicate traumatic LP more likely than SAH. Xanthochromia 
resulting from RBC lysis after centrifuging indicates SAH rather than traumatic  
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MANAGEMENT OF CVD:- 
1) MEDICAL SUPPORT 
2) INTRAVENOUS THROMBOLYSIS 
3) ENDOVASCULAR TECHNIQUES 
4) ANTITHROMBOTIC TREATMENT 
5) NEUROPROTECTION 
6) STROKE CENTRES AND REHABILITATION 
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METHODOLOGY 
STUDY: 
ASSOCIATION OF SERUM URIC ACID LEVELS IN ACUTE 
ISCHEMIC STROKE 
OBJECTIVES: 
1. The study is conducted to analyse the association between serum uric 
acid levels and acute ischemic stroke and to asses its risk factor potential. 
2. To study the association between serum uric acid levels and other risk 
factors mainly hypertension, DM, CAD and lipid profile. 
TYPE OF STUDY:   Analytical Cross Sectional Study 
STUDY POPULATION:  Patients admitted in Govt. Royapettah Hospital with 
first time acute ischemic stroke. 
Inclusion criteria: 
Patients with 1st time acute ischemic stroke 
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Exclusion criteria: 
 Previous H/o TIA, CVA 
 Patients on Thiazide diuretics 
 Patients with Malignancies 
 Patients who are a known case of gout or have clinical evidence of gout 
 Patients with chronic renal failure 
 Patients with hemorrhagic stroke 
SAMPLE SIZE:  As per formula for calculating sample size, sample size was 
found to be 50. 
METHODOLOGY: 
After obtaining consent from the patient, Serum uric acid levels will be 
checked in cases of acute ischemic stroke. 
Other risk factors including DM, Hypertension and hyperlipidemia will 
be evaluated with appropriate lab investigations. 
Association between uric acid levels and acute ischemic stroke will be analysed. 
The association between uric acid levels and other risk factors will also be 
looked for.  
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TABLE-1:     AGE DISTRIBUTION OF THE STUDY POPULATION 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
AGE GROUP 
 
FREQUENCY 
 
PERCENT 
 
  
40-50 
 
4 
 
8% 
  50-60 15 30% 
  60-70 21 42% 
  70-80 9 18% 
  > 80 1 2% 
  Total 50 100% 
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PIE DIAGRAM SHOWING AGE DISTRIBUTION OF THE STUDY 
POPULATION 
 
 
 
 
 
 
 
 Majority of the study subjects  where between the age group of 60-70 
years that is around 42%.  30% of the study subjects where in the age group of 
50-60 years. 18% of the study subjects are in the age group of 70-80 years. 8% 
of the study subjects are in 40-50 years and the remaining 2% are in the age 
group of 80 and above. 
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Table 2: SEX DISTRIBUTION OF THE STUDY POPULATION 
 
 
 
 
 
PIE DIAGRAM SHOWING SEX DISTRIBUTION OF STUDY 
POPULATION 
 
 
 
 
 
 
 
Majority of the study subjects where females which is around  66%  and the 
males were around 34%. 
SEX 
 
FREQUENCY 
 
PERCENT 
 
 Male 33 66 % 
  Female 17 34 % 
  Total 50 100% 
58 
 
Table 3: DISTRIBUTION OF THE STUDY POPULATION BASED ON 
BMI STATUS 
 
  
 
 
 
 
 
PIE DIAGRAM SHOWING DISTRIBUTION BASED ON BMI STATUS 
                                   
 Majority of the study subjects  where in the BMI status 20-24.9 , which is 
around 48%.  38% of the study subjects where in the BMI status 25-29.9. And 
the remaining 14% of the study subjects are in the BMI status 30 and above. 
    BMI  
STATUS FREQUENCY PERCENT 
 
20-24.9 
 
24 48% 
25-29.9 
19 
38% 
 
>= 30 
7 
14% 
 
Total 50 100 
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Table 4: DISTRIBUTION OF THE STUDY POPULATION 
ACCORDING TO HYPERTENSION 
 
 
 
 
 
 
PIE DIAGRAM SHOWING NUMBER OF HYPERTENSION 
                             
 Majority of the study population are hypertensive which where around 
62% .the remaining 38% were normotensive. 
HYPERTENSION 
 
FREQUENCY 
 
PERCENT 
 
 Yes 19 38% 
  No 31 62% 
   
Total 
 
50 
 
100% 
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TABLE 5: DISTRIBUTION OF THE STUDY POPULATION 
ACCORDING TO DIABETES MELLITUS 
DIABETES 
MELLITUS FREQUENCY PERCENT 
Yes 18 36 
No 32 64 
Total 50 100 
 
DIAGRAM SHOWING DISTRIBUTION ACCORDING TO DIABETES 
MELLITUS 
 
 Majority of the study subjects where non-diabetic which where around 
64%. The remaining 36% were diabetic. 
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TABLE 6: DISTRIBUTION OF THE STUDY POPULATION 
ACCORDING TO CORONARY ARTERY DISEASE 
CORONARY ARTERY DISEASE FREQUENCY PERCENT 
  
Yes 
15 30.0 
  No 35 70.0 
   
Total 
50 100.0 
 
PIE DIAGRAM SHOWING THE DISTRIBUTION OF THE STUDY 
POPULATION ACCORDING TO CORONARY ARTERY DISEASE 
 
 Majority of the study subjects have no coronary artery disease which 
where around 70%. The remaining 30% of the study population have coronary 
artery disease. 
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TABLE 7: DISTRIBUTION OF THE STUDY POPULATION 
ACCORDING TO SMOKING HABIT 
 
SMOKING HABIT FREQUENCY PERCENT 
  
YES 
 
17 34% 
  NO 33 66% 
  TOTAL 50 100% 
 
DIAGRAM SHOWING DISTRIBUTION OF THE STUDY 
POPULATION ACCORDING TO SMOKING HABIT 
 
 Majority of the study subjects are non – smokers which where around 
66%. The remaining  34% of the study subjects were smokers . 
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TABLE 8: DISTRIBUTION OF THE STUDY POPULATION 
ACCORDING TO ALCOHOL CONSUMPTION 
ALCOHOL CONSUMPTION 
 
FREQUENCY 
 
PERCENT 
 
  
Yes 
 
12 24% 
  No 38 76% 
  Total 50 100% 
 
PIE DIAGRAM SHOWING THE DISTRIBUTION OF THE STUDY 
POPULATION ACCORDING TO ALCOHOL INTAKE 
 
 Majority of the study subjects are non – alcoholic which where around 
76%. The remaining 24% were alcoholics.  
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TABLE 9: DISTRIBUTION OF THE STUDY POPULATION 
ACCORDING TO DIET PATTERN 
DIET PATTERN 
 
FREQUENCY 
 
PERCENT 
 
 Vegeterian 20 40 
  Non- Vegeterian 
 
30 60 
  Total 50 100.0 
 
PIE DIAGRAM SHOWING DISTRIBUTION OF THE STUDY 
POPULATION ACCORDING TO DIET PATTERN 
 
 Majority of the study subjects are non-vegetarians which where around 
60% . The remaining 40% were  vegetarians.  
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TABLE 10: DISTRIBUTION OF THE STUDY POPULATION 
ACCORDING TO CVA 
TYPE OF CVA 
 
FREQUENCY 
 
PERCENT 
 
 Hemiparesis 38 76.0 
  Hemiplegia 12 24.0 
   
 
TOTAL 
 
50 
 
100.0 
 
BAR DIAGRAM SHOWING DISTRIBUTION OF THE STUDY 
POPULATION ACCORDING TO CVA 
 
 Majority of the study subjects are having Hemiparesis which where 
around 76%. The remaining 24% of the study subjects are having hemiplegia. 
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TABLE 11: DISTRIBUTION OF THE STUDY POPULATION 
ACCORDING TO SERUM.CHOLESTEROL 
SERUM CHOLESTEROL 
 
FREQUENCY 
 
PERCENT 
 
 < 200 43 86.0 
  > 200 7 14.0 
   
Total 
50 100.0 
 
PIE DIAGRAM SHOWING DISTRIBUTION OF THE STUDY 
POPULATION ACCORDING TO SERUM CHOLESTEROL 
 
 Majority of the study subjects have serum cholesterol level <200 mg/dl 
which where around 86%. The remaining 14% of the study subjects have 
elevated serum cholesterol value.  
67 
 
TABLE 12: DISTRIBUTION OF THE STUDY POPULATION 
ACCORDING TO LDL LEVEL 
 
 
 
DIAGRAM SHOWING: DISTRIBUTION OF THE STUDY 
POPULATION ACCORDING TO LDL LEVEL 
               
 Majority of the study population having elevated LDL  values which 
where around 80% .The remaining 20% have normal LDL values. 
             LDL 
 
FREQUENCY 
 
PERCENT 
 
 < 100 10 20.0 
  > 100 40 80.0 
  Total 50 100.0 
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TABLE 13: DISTRIBUTION OF THE STUDY POPULATION 
ACCORDING TO TGL VALUES 
             TGL 
 
FREQUENCY 
 
PERCENT 
 
 < 150 45 90.0 
  > 150 5 10.0 
  Total 50 100.0 
 
PIE DIAGRAM SHOWING DISTRIBUTION OF STUDY POPULATION 
ACCORDING TO TGL LEVEL 
90%
10%
<150
>150
 
 Majority of the study subjects are having TGL values  normal which 
where around 90%. The remaining10% of the study subjects have elevated TGL 
levels. 
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TABLE 14: DISTRIBUTION OF THE STUDY POPULATION 
ACCORDING TO SUA 
 
BAR DIAGRAM SHOWS: DISTRIBUTION OF THE STUDY 
POPULATION ACCORDING TO SUA 
 
 
 
 
 
 Majority of the study subjects have SUA =<6.5 mg/dl  which where 
around 74%. The remaining 26% of the study subjects have elevated SUA . 
     URIC ACID 
 
FREQUENCY 
 
PERCENT 
 
<= 6.5 37 74.0 
> 6.5 13 26.0 
Total 50 100.0 
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Table  15: CROSS TABULATION  BETWEEN   DM   AND  SUA 
Crosstab 
 
  
  
  
  
Uric Acid Total P value 
<= 6.5 > 6.5   
DM Yes Count 9 9 18  
 
 
 
 
 
 
0.004** 
  
  
  
  
% within 
DM 
50.0% 50.0% 100.0% 
% within 
Uric Acid 
24.3% 69.2% 36.0% 
  
  
  
No Count 28 4 32 
  
  
% within 
DM 
87.5% 12.5% 100.0% 
% within 
Uric Acid 
75.7% 30.8% 64.0% 
 
Total 
  
  
Count 37 13 50 
% within 
DM 
74.0% 26.0% 100.0% 
% within 
Uric Acid 
100.0
% 
100.0% 100.0% 
 
p value   0 .004 
Among the study subjects 74% had  SUA less than 6.5 mg/dl compared to 
26% of the study subjects have elevated SUA (>6.5 mg/dl). It is evident from 
the study that 50% diabetic patients had there. SUA < 6.5 compared to 50% 
diabetic with elevated SUA.  
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In contrast 87.5% the non diabetic patients have SUA <6.5 and 12.5% of 
the non diabetics have SUA > 6.5. This difference was found to be statistically 
significant. 
 
BAR DIAGRAM SHOWING CORRELATION BETWEEN  DM AND 
SUA 
DM
NoYes
C
ou
nt
30
20
10
0
Uric Acid
<= 6.5
> 6.5
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Table 16: CROSS TABULATION BETWEEN  CAD AND SUA 
Crosstab 
  
  
Uric Acid 
Total 
    
<= 6.5 
> 6.5  
 
CAD      Yes Count 8 7 15 
    
% within CAD 53.3% 46.7% 100.0% 
    
% within Uric Acid 21.6% 53.8% 30.0% 
   
No 
Count 29 6 35 
    
% within CAD 82.9% 17.1% 100.0% 
    
% within Uric Acid 78.4% 46.2% 70.0%  
Total Count 37 13 50 
   
% within CAD 74.0% 26.0% 100.0% 
   
% within Uric Acid 100.0% 100.0% 100.0% 
 
p value  0.029 
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CAD
NoYes
C
ou
nt
40
30
20
10
0
Uric Acid
<= 6.5
> 6.5
Among the study subjects 74% had  SUA less than 6.5 mg/dl compared to 
26% of the study subjects have elevated SUA (>6.5 mg/dl).It is evident from the 
study that 53.3%  CAD patients had there  SUA < 6.5compared to 46.7% of the 
CAD patients  with elevated SUA .  
In contrast 82.9% the non CAD subjects have SUA <6.5 and 17.1% of 
the non CAD subjects have SUA > 6.5. This difference was found to be 
statistically significant. 
BAR DIAGRAM SHOWING CORRELATION BETWEEN CAD AND 
SUA 
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Table 17: CROSS TABULATION BETWEEN SMOKING AND SUA 
Crosstab 
    
Uric Acid 
Total 
    
<= 6.5 
> 6.5  
 
Smoking      Yes Count 11 6 17 
    
% within Smoking 64.7% 35.3% 100.0% 
    
% within Uric Acid 29.7% 46.2% 34.0% 
   
No 
Count 26 7 33 
    
% within Smoking 78.8% 21.2% 100.0% 
    
% within Uric Acid 70.3% 53.8% 66.0%  
Total Count 37 13 50 
   
% within Smoking 74.0% 26.0% 100.0% 
   
% within Uric Acid 100.0% 100.0% 100.0% 
 
p  value    0.282 
 
Among the study subjects 74% had  SUA less than 6.5 mg/dl compared to 26% 
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Smoking
NoYes
C
ou
nt
30
20
10
0
Uric Acid
<= 6.5
> 6.5
of the study subjects have elevated SUA (>6.5 mg/dl).It is evident from the 
study that 64.7%  smoking patients had there  SUA < 6.5 compared to32.5% of 
the smoking  patients  with elevated SUA . In contrast 78.8% of the non 
smoking subjects have SUA <6.5 and 21.2% of the non smoking subjects have 
SUA > 6.5. This difference was found to be statistically in significant. 
BAR DIAGRAM SHOWING CORRELATION BETWEEN SMOKING 
AND SUA 
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Table  18 : CROSS TABULATION  BETWEEN  ALCOHOL AND SUA 
Crosstab 
    
Uric Acid 
Total 
    
<= 6.5 
> 6.5  
 
Alcohol      Yes Count 5 7 12 
    
% within Alcohol 41.7% 58.3% 100.0% 
    
% within Uric Acid 13.5% 53.8% 24.0% 
   
No 
Count 32 6 38 
    
% within Alcohol 84.2% 15.8% 100.0% 
    
% within Uric Acid 86.5% 46.2% 76.0%  
Total Count 37 13 50 
   
% within Alcohol 74.0% 26.0% 100.0% 
   
% within Uric Acid 100.0% 100.0% 100.0% 
 
p  value    0.003 
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Alcohol
NoYes
C
ou
nt
40
30
20
10
0
Uric Acid
<= 6.5
> 6.5
Among the study subjects 74% had  SUA less than 6.5 mg/dl compared to 
26% of the study subjects have elevated SUA (>6.5 mg/dl).It is evident from the 
study that 41.7%  of  alcoholic patients had there  SUA < 6.5 compared to58.3% 
of the alcoholic patients  with elevated SUA .  
In contrast 84.2% of the non alcoholic subjects have SUA <6.5 and 
15.8% of the non alcoholic subjects have SUA > 6.5. This difference was found 
to be statistically  significant. 
 
BAR DIAGRAM SHOWING CORRELATION BETWEEN ALCOHOL 
AND SUA 
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Table 19: CROSS TABULATION BETWEEN DIET AND SUA 
    
Uric Acid 
Total 
    
<= 6.5 
> 6.5  
 
Diet      Vegeterian Count 18 2 20 
    
% within Diet 90.0% 10.0% 100.0% 
    
% within Uric 
Acid 
48.6% 15.4% 40.0% 
   
Non-
Vegeterian 
Count 19 11 30 
    
% within Diet 63.3% 36.7% 100.0% 
    
% within Uric 
Acid 
51.4% 84.6% 60.0% 
 
Total Count 37 13 50 
   
% within Diet 74.0% 26.0% 100.0% 
   
% within Uric 
Acid 
100.0% 100.0% 100.0% 
 
p  value    0.035 
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Among the study subjects 74% had  SUA less than 6.5 mg/dl compared to 
26% of the study subjects have elevated SUA (>6.5 mg/dl).It is evident from the 
study that 90% of  vegetarian patients had there  SUA < 6.5 compared to10% of 
the vegetarian patients  with elevated SUA .  
In contrast 63.3% of the non vegetarian subjects have SUA <6.5 and 36.7% of 
the non vegetarian subjects have SUA > 6.5. This difference was found to be 
statistically significant. 
BAR DIAGRAM SHOWING CORRELATION BETWEEN DIET AND 
SUA 
Diet
Non-VegeterianVegeterian
C
ou
nt
20
10
0
Uric Acid
<= 6.5
> 6.5
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Table:20 CROSS TABULATION BETWEEN  TYPE OF CVA AND SUA 
    
Uric Acid 
Total 
    
<= 6.5 
> 6.5  
 
Type of CVA      Hemiparesis Count 37 1 38 
    
% within Type of 
CVA 
97.4% 2.6% 100.0% 
    
% within Uric Acid 100.0% 7.7% 76.0% 
   
Hemiplegia 
Count 0 12 12 
    
% within Type of 
CVA 
.0% 100.0% 100.0% 
    
% within Uric 
Acid 
.0% 92.3% 24.0% 
 
Total Count 37 13 50 
   
% within Type of 
CVA 
74.0% 26.0% 100.0% 
   
% within Uric Acid 100.0% 100.0% 100.0% 
 
p  value    0.000 
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Type of CVA
HemiplegiaHemiparesis
C
ou
nt
40
30
20
10
0
Uric Acid
<= 6.5
> 6.5
Among the study subjects 74% had  SUA less than 6.5 mg/dl compared to 
26% of the study subjects have elevated SUA (>6.5 mg/dl).It is evident from the 
study that 97.4%  Hemiparesis patients had there  SUA < 6.5 compared to2.6% 
of the Hemiparesis patients  with elevated SUA .  
In contrast 0% of the Hemiplegia subjects have SUA <6.5 and 100% of 
the Hemiplegia subjects have SUA > 6.5. This difference was found to be 
statistically significant. 
BAR DIAGRAM SHOWING CORRELATION BETWEEN TYPE OF 
CVA AND SUA 
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Table 21: CROSSTABULATION BETWEEN TOTAL CHOLESTEROL 
AND SUA 
    
Uric Acid 
Total 
    
<= 6.5 
> 6.5  
 
Total Cholesterol 
(Mg/Dl) 
     < 
200 
Count 36 7 43 
    
% within Total Cholesterol 
(Mg/Dl) 
83.7% 16.3% 100.0% 
    
% within Uric Acid 97.3% 53.8% 86.0% 
   
> 
200 
Count 1 6 7 
    
% within Total Cholesterol 
(Mg/Dl) 
14.3% 85.7% 100.0% 
    
% within Uric Acid 2.7% 46.2% 14.0%  
Total Count 37 13 50 
   
% within Total Cholesterol 
(Mg/Dl) 
74.0% 26.0% 100.0% 
   
% within Uric Acid 100.0% 100.0% 100.0% 
 
p  value    0.000 
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Total Cholesterol (Mg/Dl)
> 200< 200
C
ou
nt
40
30
20
10
0
Uric Acid
<= 6.5
> 6.5
Among the study subjects 74% had  SUA less than 6.5 mg/dl compared to 
26% of the study subjects have elevated SUA (>6.5 mg/dl).It is evident from the 
study that 83.7%  of  patients with total cholesterol (<200mg/dl)  had there  
SUA < 6.5 compared to16.3% of the  patients  with total cholesterol 
(<200mg/dl)  had elevated SUA .  
In contrast 14.3% of the patients with total cholesterol (>200mg/dl) had 
SUA <6.5 and 85.7% of the patient with total cholesterol (>200mg/dl) had  
SUA > 6.5. This difference was found to be statistically significant. 
 
BAR DIAGRAM SHOWING CORRELATION BETWEEN TOTAL 
CHOLESTEROL AND SUA 
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Table 22: CROSS TABULATION BETWEEN   LDL AND SUA 
    
Uric Acid 
Total 
    
<= 6.5 
> 6.5  
 
LDL (MG/DL)      < 
100 
Count 10 0 10 
    
% within LDL 
(MG/DL) 
100.0% .0% 100.0% 
    
% within Uric Acid 27.0% .0% 20.0% 
   
> 
100 
Count 27 13 40 
    
% within LDL 
(MG/DL) 
67.5% 32.5% 100.0% 
    
% within Uric 
Acid 
73.0% 100.0% 80.0% 
 
Total Count 37 13 50 
   
% within LDL 
(MG/DL) 
74.0% 26.0% 100.0% 
   
% within Uric Acid 100.0% 100.0% 100.0% 
 
p  value    0.036 
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Among the study subjects 74% had  SUA less than 6.5 mg/dl compared to 
26% of the study subjects have elevated SUA (>6.5 mg/dl).It is evident from the 
study that 100%  of  patients with LDL (<100mg/dl)  had there  SUA < 6.5 
compared to 0% of the  patients  with  LDL (<100mg/dl)  had elevated SUA .  
In contrast 67.5% of the patients with LDL (>100mg/dl) had SUA <6.5 
and 32.5% of the patient with LDL (100mg/dl) had SUA > 6.5. This difference 
was found to be statistically significant. 
BAR DIAGRAM SHOWING CORRELATION BETWEEN LDL  AND 
SUA 
LDL (MG/DL)
> 100< 100
C
ou
nt
30
20
10
0
Uric Acid
<= 6.5
> 6.5
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Table 23: CROSS TABULATION BETWEEN TGL AND SUA 
    
Uric Acid 
Total 
    
<= 6.5 
> 6.5  
 
TGL (MG/DL)      < 150 Count 34 11 45 
    
% within TGL (MG/DL) 75.6% 24.4% 100.0% 
    
% within Uric Acid 91.9% 84.6% 90.0% 
   
> 150 
Count 3 2 5 
    
% within TGL (MG/DL) 60.0% 40.0% 100.0% 
    
% within Uric Acid 8.1% 15.4% 10.0%  
Total Count 37 13 50 
   
% within TGL (MG/DL) 74.0% 26.0% 100.0% 
   
% within Uric Acid 100.0% 100.0% 100.0% 
 
p  value    0.452 
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Among the study subjects 74% had  SUA less than 6.5 mg/dl compared to 
26% of the study subjects have elevated SUA (>6.5 mg/dl).It is evident from the 
study that  75.6%  of  patients with TGL (<150mg/dl)  had there  SUA < 6.5 
compared to24.4% of the  patients  with TGL(<150mg/dl)  had elevated SUA .  
In contrast 60% of the patients with TGL (>150mg/dl) had SUA <6.5 and 40% 
of the patient with TGL (>150mg/dl) had SUA > 6.5. This difference was found 
to be statistically in significant. 
 
BAR DIAGRAM SHOWING CORRELATION BETWEEN TGL AND 
SUA 
TGL (MG/DL)
> 150< 150
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ou
nt
40
30
20
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Uric Acid
<= 6.5
> 6.5
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Table 24: CROSS TABULATION BETWEEN AGE AND SEX 
  
    
Sex 
Total 
    
Male 
Female  
 
Age in years      40-50 Count 4 0 4 
    
% within Age in years 100.0% .0% 100.0% 
    
% within Sex 12.1% .0% 8.0% 
   
50-60 
Count 11 4 15 
    
% within Age in years 73.3% 26.7% 100.0% 
    
% within Sex 33.3% 23.5% 30.0% 
   
60-70 
Count 11 10 21 
    
% within Age in years 52.4% 47.6% 100.0% 
    
% within Sex 33.3% 58.8% 42.0% 
   
70-80 
Count 6 3 9 
    
% within Age in years 66.7% 33.3% 100.0% 
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% within Sex 18.2% 17.6% 18.0% 
   
> 80 
Count 1 0 1 
    
% within Age in years 100.0% .0% 100.0% 
    
% within Sex 3.0% .0% 2.0%  
Total Count 33 17 50 
   
% within Age in years 66.0% 34.0% 100.0% 
   
% within Sex 100.0% 100.0% 100.0% 
 
p value – 0.34 
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BAR DIAGRAM SHOWING CORRELATION BETWEEN AGE AND 
SEX 
Age in years
> 8070-8060-7050-6040-50
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DISCUSSION 
         This study, conducted at The Department of Internal Medicine, GOVT 
ROYAPETTAH HOSPITAL, and KILPAUK MEDICAL COLLEGE included 
the patients with acute ischemic stroke. Levels of serum uric acid were studied 
within 24 hours of admission. The SUA was taken after 4-6 hours of fasting. 
The mean value of SERUM URIC ACID (SUA) was taken as 6.5 mg / dl. The 
value was compared with various risk factors of the CVD. 
          About 50 patients participated in the study of which 33 (66%) were male 
and 17(34%) were female. In the study 38% of the patients were below 60 years 
and 62% of the patients were above 60 years. The study revealed that the 
correlation between the age and the level of uric acid was insignificant with p 
value >0.05  
         In the study about 48% of the study population had BMI <24.9 and 52% 
of the study population had a BMI>25. The study revealed the correlation 
between the BMI and uric acid as significant with p value <0.05 
         In the study about 38% of the study population were hypertensive and 
62% were normotensive. The study revealed the association between the 
hypertension and uric acid as significant with p value <0.05 
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         In the study about 36% of the study population were diabetic and 64% 
were non diabetic. The study revealed the association between the diabetes and 
uric acid as significant with p value <0.04 
          In the study about 30% of the study population were CAD patient and 
70% were non CAD patients. The study revealed the association between the 
CAD and uric acid as significant with p value <0.029 
          In the study about 34% of the study population were smokers and 66% 
were non smokers . The study revealed the association between the smoking 
and uric acid as insignificant with p value <0.2  
        In the study about 26% of the study population were alcoholics and 74% 
were non alcoholic. The study revealed the association between the alcohol and 
uric acid as significant with p value <0.05.                                                                                                                                      
         In the study about 40% of the study population were vegetarian and 60% 
were non vegetarian . The study revealed the association between the diet and 
uric acid as significant with p value <0.035. 
          In the study about 76%  of the study population were hemiparetic and 
24% were hemiplegic. The study revealed the association between the 
hemiparesis and hemiplegia with elevated uric acid as significant with p value 
<0.05. 
93 
 
         In the study about 86% of the study population have normal cholesterol 
and 14% have high cholesterol . The study revealed the association between the 
cholesterol and uric acid as significant with p value <0.05 
         In the study about 20% of the study population have normal LDL and 80% 
have high LDL. The study revealed the association between LDL and uric acid 
as significant with p value <0.05 
        In the study about 76% of the population have uric acid <6.5mg/dl and 
24% of the population uric acid level > 6.5. This result reveals that serum uric 
acid was elevated in patients with acute ischemic stroke. This study also reveals 
that the association between uric acid with DM, CAD, SHT, alcohol, 
dyslipidemia is significant . The study also reveals that the association between 
SUA with smoking and age is insignificant. Serum uric acid, the strong anti 
oxidant, under certain circumstances like absence of other anti-oxidants may act 
as pro-oxidant. Thus serum uric acid may be taken as a marker of elevated risk 
of cerebrovascular accident. 
          The precise role of uric acid in vascular disease is to be studied and 
researched further. 
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CONCLUSION 
1) This study shows that elevated SERUM URIC ACID is strongly 
associated with an increased risk for the development of acute ischemic/ 
non-embolic stroke in this study population. 
2) SERUM URIC ACID is the substance with both anti inflammatory  and 
pro-inflammatory activity 
3) Elevated SUA can be considered as one of the risk factors for acute 
ischemic non-embolic stroke. 
4) Elevated serum uric acid is found to be strongly associated with various 
risk factors of non-communicable disease  
5) Lowering of SUA level can be considered as one of the preventive 
modalities for stroke while treating high risk population. 
6) It is also suggested that further studies are required to assess whether 
lowering of  SUA  level  with  drugs  can  actually  reduce  the  risk  of 
ischemic stroke. 
 LIMITATIONS OF THE STUDY 
 Short duration of the study 
 Small sample size. 
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PATIENT CONSENT FORM 
STUDY DETAIL: 
STUDY CENTRE: 
PATIENT’S NAME: 
PATIENT’S AGE: 
IDENTIFICATION NUMBER: 
I confirm that I have understood the purpose and procedure of the above 
study. I have the opportunity to ask questions and all my questions and doubts 
have been answered to my complete satisfaction. 
I understand that my participation in the study is voluntary and that I am 
free to withdraw at any time without giving reason, without my legal rights 
being affected. 
I understand that the ethical committee and the regulatory authorities will 
not need my permission to look at my health records, both in respect of the 
current study and any further research that may be conducted in relation to it, 
even if I withdraw from the study I agree to this access. However I understand 
that my identity would not be revealed, and any information released to third 
parties or published, unless as required under the law. I agree not to restrict the 
use of any data or results that arise from this study. 
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I hereby consent to participate in this study. 
I hereby give permission to undergo complete clinical examination and 
diagnostic tests including haematological, biochemical, radiological tests. 
Signature/thumb impression: 
Patient’s name and address:                                             Place:                              
Date: 
Signature of the investigator: 
Name of the investigator:                                                  Place:                              
Date: 
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PROFORMA 
NAME:      
AGE:   SEX:    
OCCUPATION: 
ADDRESS: 
EDUCATIONAL STATUS OF THE PATIENT: 
PRESENTING COMPLAINTS: 
DURATION OF PRESENTING COMPLAINTS: 
Weakness of limbs : 
Speech disturbance: 
LOC; 
Seizures: 
Bladder and bowel disturbance: 
Gait disturbance: 
Imbalance and sway: 
Vomiting: 
Fever: 
Headache: 
Trauma: 
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Visual disturbances: 
Chest pain: 
Palpitations: 
PAST HISTORY: 
Diabetes Mellitus: 
Hypertension: 
Old history of CVA: 
CAD: 
RHD: 
LVF: 
CKD: 
Gout: 
Malignancies: 
Thiazide intake: 
H/o Urate renal stones: 
PERSONAL HISTORY: 
Alcohol: 
Smoking: 
Blood transfusions: 
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GENERAL EXAMINATION: 
SYSTEMIC EXAMINATION: 
CVS : 
RS: 
ABDOMEN: 
CNS:  
PARAMETERS MEASURED: 
Weight of the patient. 
BP: 
PULSE: 
LAB VALUES: 
1. Serum Uric acid 
2. Lipid profile 
3. Fasting and PPBS in Diabetic patients 
4. Renal function tests. 
5. Electrolytes 
6. CBC with Peripheral smear 
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